Paul D. Bieniasz

This study develops multivalent anti-ACE2 nanobodies that broadly neutralize SARS-CoV-2 variants and sarbecoviruses with high potency and efficacy in animal models.

This study identifies two antibodies that recognize conserved SARS-CoV-2 RBD epitopes, revealing structural mechanisms for broad neutralization and escape pathways.

This study shows that the coronavirus nuclease NSP15 drives insertion mutations, which can enhance viral transmissibility, as seen in the SARS-CoV-2 furin cleavage site.

This study identifies RNF213 as an IFN-gamma-induced antiviral protein that inhibits coronavirus translation by targeting nascent double membrane vesicles.

This paper designs an overlapping variant immunogen pool that elicits broad neutralization against SARS-CoV-2 variants and a chimeric SARS-CoV-1 virus.

This study shows that re-infection with SARS-CoV-2 leads to broader and more potent antibodies against diverse sarbecovirus strains compared to antibodies from a prior infection.

This study characterizes HIV reservoir clones and shows they can be culled by sustained CTL pressure, with some displaying intrinsic resistance linked to low oxidative stress.

This study investigates how HIV-1 integration sites influence viral latency and clonal expansion in human memory CD4+ T cells engrafted into mice.

PRISM-seq is an ultra-sensitive method for detecting lentiviral integration sites, validated at the single-molecule level with a quality control framework to reduce artifacts.

This study compares memory B cell responses to mRNA and nanoparticle vaccines in mice, finding similar antibody sequences but better breadth from mosaic nanoparticle vaccines.

This study examines memory and germinal center B cell responses in rhesus macaques after booster immunization, finding that high affinity memory B cells form a reservoir that participates in immune development regardless of boosting site.

This study determines the structural plasticity of HIV-1 RRE stem-loop II and shows how it modulates Rev binding and nuclear export of viral RNA.

This paper develops mosaic RBD-nanoparticles to induce cross-reactive anti-sarbecovirus antibodies in animals, demonstrating their effectiveness against SARS-CoV-2 variants and zoonotic viruses.

The paper designs bispecific antibodies that retain neutralization activity against multiple SARS-CoV-2 variants, including Omicron subvariants.

This study identifies cross-reactive antibodies against SARS-CoV-2 and related sarbecoviruses that target conserved epitopes and show broad neutralization potential.